CAJ | 학술논문

目的观察依达拉奉对急性脑梗死患者血清炎症因子白细胞介素-6(IL-6)、肿瘤坏死因子(TNF-α)和超敏C反应蛋白(hs-CRP)水平的影响.方法选择急性脑梗死患者120例,随机分为依达拉奉组60例和常规治疗组60例,选择门诊健康体检者60例作为正常对照组.所有脑梗死患者均于人院时、治疗后3 d、7 d、14 d分别抽静脉血3 ml检测血清中IL-6、TNF-α、hs-CRP含量各1次,门诊健康体检者仅测定1次血清IL-6、TNF-α、hs-CRP含量.结果脑梗死患者血清IL-6、TNF-α及hs-CRP浓度水平较健康体检组明显升高(P＜0.01).依达拉奉组和常规治疗组治疗前血清IL-6、TNF-α及hs-CRP含量测定无明显差异(P＞0.05),治疗后依达拉奉组血清IL-6、TNF-α浓度治疗后3 d、7 d和14 d逐步下降,较常规治疗组有显著差异(P＜0.01).依达拉奉组治疗后7 d和14 d血清hs-CRP浓度含量测定明显降低(P＜0.05和P＜0.01);常规治疗第14天血清hs-CRP浓度才明显降低(P＜0.05);两组间治疗第7天和第14天有显著差异(P＜0.05).依达拉奉对于中重度病情患者的血清IL-6、TNF-α、hs-CRP水平的影响比轻度病情患者影响更大.结论急性脑梗死患者血清IL-6、TNF-α和hs-CRP含量明显增加,依达拉奉能显著降低急性脑梗死患者血清炎症因子IL-6、TNF-α和hs-CRP的水平,且对病情重者影响更明显.
목적 관찰의체랍봉대급성뇌경사환자혈청염증인자백세포개소-6(IL-6)、종류배사인자(TNF-α)화초민C반응단백(hs-CRP)수평적영향.방법 선택급성뇌경사환자120례,수궤분위의체랍봉조60례화상규치료조60례,선택문진건강체검자60례작위정상대조조.소유뇌경사환자균우인원시、치료후3 d、7 d、14 d분별추정맥혈3 ml검측혈청중IL-6、TNF-α、hs-CRP함량각1차,문진건강체검자부측정1차혈청IL-6、TNF-α、hs-CRP함량.결과 뇌경사환자혈청IL-6、TNF-α급hs-CRP농도수평교건강체검조명현승고(P＜0.01).의체랍봉조화상규치료조치료전혈청IL-6、TNF-α급hs-CRP함량측정무명현차이(P＞0.05),치료후의체랍봉조혈청IL-6、TNF-α농도치료후3 d、7 d화14 d축보하강,교상규치료조유현저차이(P＜0.01).의체랍봉조치료후7 d화14 d혈청hs-CRP농도함량측정명현강저(P＜0.05화P＜0.01);상규치료제14천혈청hs-CRP농도재명현강저(P＜0.05);량조간치료제7천화제14천유현저차이(P＜0.05).의체랍봉대우중중도병정환자적혈청IL-6、TNF-α、hs-CRP수평적영향비경도병정환자영향경대.결론 급성뇌경사환자혈청IL-6、TNF-α화hs-CRP함량명현증가,의체랍봉능현저강저급성뇌경사환자혈청염증인자IL-6、TNF-α화hs-CRP적수평,차대병정중자영향경명현.
Objective To study the effects of edaravone on levels of inflammatory factors interleukin -6(IL-6), tumor necrosis factor -α(TNF-α) and high sensitive C-reactive protein (hs-CRP) in patients with acute cerebral infarction. Methods 120 patients with acute cerebral infarction were randomly divided into edara vone group( n = 60)and conventional therapy group( n =60) ,and 60 cases healthy were selected as the normal control group. Respectively 3 ml venous blood of all patients with cerebral infarction were collected at the time of admission, the 3 d, 7 d and 14 d after treatment. Then the serum IL-6, TNF-α and hs-CRP levels of all patients were detected. Results The IL-6, TNF-α and hs-CRP levels in cerebral infarction patients were significantly higher than those in healthy subjects ( P ＜ 0. 01 ). There were no significant difference ( P ＞ 0.05 ) in levels of IL-6, TNF-α and hs-CRP between edaravone group and conventional treatment group before treatment. With the time prolonged, the levels of IL-6, TNF-α in edaravone group were gradually decreased at the 3 d,7 d and 14 d after treatment, and were significantly different compared with conventional treatment group (P ＜ 0. 01 ). The hs-CRP levels in edaravone group decreased significantly at the 7 d, 14 d after treatment ( P ＜ 0. 05 and P ＜0. 01 ) ,where as those in conventional treatment group showed significantly decreased at the 14 d after treatment ( P ＜ 0. 05 ) compared with those of before treatment, and the hs-CRP levels in edaravone group were higher than those in conventional treatment group at the 7 d and 14 d ( P ＜ 0.05 ). Edaravone had more apparent effects on the IL-6, TNF-α, hs-CRP levels in patients with moderate and severe damage than those in patients with mild damage. Conclusion The IL-6, TNF-α and hs-CRP levels in patients with acute cerebral infarction are significantly increased than those in normal group. Edaravone could significantly decrease the inflammatory factor IL-6, TNF-α and hs-CRP levels, and have more effects on patients with severe damage.